Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04365673 · ClinicalTrials.gov registry record
LACE+ and MRS Score Readmission Rate Assessment
A clinical trial, sponsored by Tabula Rasa HealthCare.
- Terminated
- Registry status
- 100
- Enrollment target
NCT04365673: Clinical Trial study, sponsored by Tabula Rasa HealthCare.
NCT04365673 is a clinical trial that was terminated before completion, run by Tabula Rasa HealthCare. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04365673 was terminated before completion, sponsored by Tabula Rasa HealthCare.
- TERMINATED
- Registry status
- 100 participants
- Enrollment target
Study Summary
A study to demonstrate that the LACE+ score in non-inferior to the medication risk score when predicting 30-day readmission post hospital discharge.
Primary Outcome
Readmission within 30-days post hospital discharge
Interventions
- OTHER Pharmacist transition of care consultation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-07-07 |
| Est. Completion | 2021-03-01 |
Why NCT04365673 stopped before completion
NCT04365673 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Pharmacist transition of care consultation is the first listed.
NCT04365673 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04365673 about?
NCT04365673 is a clinical study titled "LACE+ and MRS Score Readmission Rate Assessment". A study to demonstrate that the LACE+ score in non-inferior to the medication risk score when predicting 30-day readmission post hospital discharge.
What is the current status of trial NCT04365673?
This trial is currently terminated. The enrollment target is 100 participants. The study started on 2020-07-07. Estimated completion is 2021-03-01.
What interventions are being tested in trial NCT04365673?
The interventions under investigation include: Pharmacist transition of care consultation (OTHER).
Who is sponsoring clinical trial NCT04365673?
This trial is sponsored by Tabula Rasa HealthCare, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI